focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
FAB is a well kept secret.
Future royalty streams in the 10’s of millions not prices in
Developing the optimal monoclonal antibody library with a future value expected to be in the £billion range
But don’t take my word fast forward to 54 mins on the link below.
https://www.investormeetcompany.com/investor/meeting/interim-results-presentation-1
Zac calling target £3 if we close on weekly at about 1.44.
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-10th-march-2021/
On Sharetalk bulletin board hero’s Zac calling target £3 over coming months if we can close at weekly highs of 1.44 ish.
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-10th-march-2021/
Good article which shows what we have in the market a monoclonal Antibody Fusion Developed for Aqualung targeting ARDS ans other lung problems as well as prostate cancer.
https://bestwirenews.com/2021/02/22/inflammatory-protein-identified-in-published-studies-as-a-key-culprit-in-covid-19-deaths-and-hospitalizations/
I am recommending this to all my friends and family as a very nice medium term growth investment. A good multibag opportunity here.
Massively under the radar. Wait till the market wakes up.
The very limited free float will mean price movements can be quite jumpy.
Twist bioscience is now valued at $9 billion. £6.4 billion not million but billions
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
It’s just a service company like Fusion. ?
The optimal platform will be worth multiple times the current market cap. !!
Once the markets wake up.
Twist is valued at 100 times revenue and FAB is valued at less than 10 times revenue.
Maybe we should be listed on Nasdaq ?
Must’ve worth a punt.
Has our new man seen enough to make a comment yet.
What about enough to decide wether to purchase a few shares to show allegiance with his new shareholders.
Must be aware what’s occurring now.
He’s already hinted “it’s a great way to start 2021 which promises to be another exciting year for the company , with a number of new exciting developments in the pipeline”
That sure sounds like a big hint to me that 2021 is going to be a good year for Fusion Antibodies
When do people start buying into that ??
After news will be hard it’s to illiquid.
Surely that’s something we can soon here about ?